Surgery Doctors in Olean, NY Accepting Medicare

9 Surgery doctors found. Showing 1 - 9

Safiullah M Malik, MD FACS Surgery Medicare: Accepting Medicare Assignments Practice Location: 2223 W State St, Suite 109, Olean, NY 14760 Phone: 716-372-3474    Fax: 716-372-4370

Arthur Martin Goldstein, MD Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 623 Main St, Olean, NY 14760 Phone: 716-237-5775    Fax: 716-375-7580

Zahid M Chohan, MD PC Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 2223 West State St, Ste 101, Olean, NY 14760 Phone: 716-372-2228    Fax: 716-372-2305

Dr. Robert Lee Jones, MD Surgery Medicare: Medicare Enrolled Practice Location: 515 Main St, Olean, NY 14760 Phone: 716-373-2600

Dr. Rachel Raphael, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2666 W State St, Olean, NY 14760 Phone: 716-701-1700    Fax: 716-701-1717

Dr. John Peter Robert, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 535 Main St, Olean, NY 14760 Phone: 716-372-0141    Fax: 716-372-6421

Dadrie Freda Baptiste, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2666 W State St, Olean, NY 14760 Phone: 716-701-1700    Fax: 716-701-1717

Dr. Eduardo Javier Morales-vicente, MD Surgery Medicare: Medicare Enrolled Practice Location: 2666 W State St, Olean, NY 14760 Phone: 716-701-1700

Rajkumar Jeganathan, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 535 Main St, Olean, NY 14760 Phone: 716-372-0141    Fax: 716-376-2349

News Archive

Wireless earphones shown to be source of carcinogenic radiation

Wireless earphones, such as those sold by tech giants Apple and Samsung, could be releasing potentially carcinogenic radiation into the heads of the users.

Sleep + exercise + diet = good health for obstructive sleep apnea patients

Research has shown a strong relationship between weight and obstructive sleep apnea (OSA). Your neck gets thicker as you gain weight.

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

Scientists investigate pathogen transmission and awareness of common wildlife-associated zoonoses

In the tropics and subtropics, families and communities frequently rely on bushmeat for food security as well as basic income. So, while the harvest and trade of wildlife are illegal in many locales, the practice is commonplace, and with it comes the potential for transmission of a zoonotic disease among human populations.

Read more Medical News

› Verified 6 days ago